Profound Medical Corp Q2 2025 Earnings: Revenue Misses Estimate, EPS at -$0.52

Profound Medical Corp reported Q2 2025 revenue of $2.2M, falling short of the analyst estimate of $3.41M. The company faced challenges with short-term delays in completing TULSA-PRO capital sales. Despite a revenue shortfall, Profound Medical Corp achieved a significant gross margin expansion to 73% and had a cash position of $35.2M as of June 30, 2025. The CEO noted potential for revenue recovery in subsequent quarters as sales are completed.

Profound Medical Corp (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in customizable, AI-powered, incision-free therapies, reported its unaudited financial results for the second quarter ended June 30, 2025. The company's revenue for the quarter was approximately $2.2 million, falling short of the analyst estimate of $3.41 million. Despite the revenue shortfall, Profound Medical Corp achieved a significant gross margin expansion to 73% and maintained a robust cash position of $35.2 million as of June 30, 2025.

The company's business highlights included a 10% sequential increase in "same store" procedure volumes and a growing TULSA-PRO® qualified sales pipeline, which now stands at 80 new systems in various stages of classification. Profound Medical Corp also reported a diverse patient mix, with 79% treated for prostate cancer only, 17% for both prostate cancer and benign prostatic hyperplasia (BPH), 3% for salvage, and 1% for BPH only.

Challenges were noted in completing TULSA-PRO® capital sales, with the CEO, Arun Menawat, stating that these delays, if completed during the quarter, would have added over $3 million to total revenues. Menawat expressed confidence in the company's ability to achieve total year-over-year revenue growth at an approximate range of 70% to 75% in 2025, driven by the large and growing TULSA-PRO® system capital sales pipeline and strong TULSA procedure volume growth.

The second quarter 2025 revenue of $2.2 million was essentially unchanged from the same period in 2024. Gross margin expansion was primarily due to manufacturing operating at higher efficiency rates based on recent improvements. Total operating expenses for the second quarter 2025 were approximately $15.4 million, up from $9.3 million in the prior year period, reflecting increased headcount, enrollment for clinical trials, sales force expansion, and other growth-related costs. The net loss for the quarter was approximately $15.7 million, or $0.52 per common share, compared to $6.9 million, or $0.28 per common share, in the prior year period.

Profound Medical Corp continues to focus on the commercialization of its technologies, including TULSA-PRO® and Sonalleve®. The company remains on track to initiate sales of its combined total prostate solution with Siemens Healthineers before the end of 2025, subject to the completion of the integration of TULSA-PRO® and the Magnetom Free.Max magnetic resonance (MR) scanner. Profound Medical Corp also announced the appointment of Leonard Wheeler as Global Ambassador for TULSA-PRO®, aiming to drive global awareness and advocacy for the system.

For complete financial results, interested parties can refer to Profound Medical Corp's filings available on its website and through the SEDAR and SEC portals.

References:
[1] https://www.biospace.com/press-releases/profound-medical-announces-second-quarter-2025-financial-results